Business Model & Strategy
Business Model
Octavian is an innovative and growing biopharmaceutical company developing a portfolio of prescription medicines targeting the Endocannabinoid System (ECS) for approval by key regulatory agencies worldwide, bringing relief to people living with debilitating conditions.
-
Octavian is an innovative and growing biopharmaceutical company developing a portfolio of prescription medicines targeting the Endocannabinoid System (ECS) for approval by key regulatory agencies worldwide, bringing relief to people living with debilitating conditions.
We are a pre-revenue, milestone-driven biopharmaceutical company, focused on advancing our programmes through key clinical development stages to create value in our business. Our programmes aim to leverage the potential of the ECS to develop new prescription medicines for people living with debilitating conditions.
Strategy
Octavian has established a pipeline of three categories of compounds, from which it is developing medicines that target the endocannabinoid system and address significant unmet medical needs including rare diseases:
New Chemical Entities (NCEs): Fully synthetic molecules designed to interact with the endocannabinoid system, offering novel mechanisms of action distinct from plant-derived cannabinoids.
In-Licensed Compounds: Selected from leading pharmaceutical sources, these compounds accelerate development timelines and enhance therapeutic potential.
Octavian Proprietary Compounds: A library of proprietary derivatives designed to optimise drug-like characteristics and expand treatment possibilities.
-
This three-pronged strategy enables us to balance risk, value, and time to market while ensuring market exclusivity and strong patent protection across all our key activities.
We have developed a proprietary library of approximately 2,000 compounds, including 14 patent families, providing a source of future drug candidates to enter our pipeline. These compounds are screened by academic and commercial partners in disease model assays. Our proprietary derivatives are designed to optimise drug-like characteristics, with chemical modifications creating new molecules that offer the potential for composition of matter patent protection, enabling us to target both common and rare diseases.
Due to the highly patentable nature of our proprietary compounds, we believe we can address a wide range of pain-related indications with a traditional patent protection strategy. In parallel, by pursuing an orphan drug strategy, we can utilise off-patent compounds to develop treatments for rare diseases that might otherwise go unaddressed, potentially bringing new approved medicines to people currently living with debilitating conditions.
Additionally, we may in-license compounds that complement our pipeline. In-licensing drug candidates that have successfully progressed through one or more stages of development provides an opportunity to accelerate clinical timelines, diversify our portfolio, and expand our ability to target both large-market and orphan indications.
Company Information
Oxford Cannabinoid Technologies Holdings PLC, trading as Octavian, is incorporated under the laws of England and Wales under the Companies Act 2006 with company number 13179529. It is headquartered in the UK, with subsidiaries in the US and Australia.
Company
presentation
